Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 6:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 184 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Fresno, California • Northridge, California • Miami, Florida + 14 more
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

NCT02496780
Conditions
Cystic Fibrosis
Interventions
novolog insulin, levemir insulin, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Conditions
Diabetes type1, Obesity
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Schizophrenia
Interventions
Insulin or Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Diabetes Mellitus, Adult Onset
Interventions
Cinnamon or placebo 500 mg capsule twice daily
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086
Conditions
Type 1 Diabetes
Interventions
Insulin Degludec, Insulin Glargine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Diabetes
Interventions
Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
Pulmonary Artery Hypertension
Interventions
Metformin, Placebo, mHealth Intervention, Usual Care
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashvile, Tennessee
Conditions
Diabetes
Interventions
Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Conditions
Femoral Shaft Fracture, Tibial Shaft Fracture
Interventions
GIK solution, Isotonic Normal Saline Solution
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Nasal Insulin to Fight Forgetfulness - Device Study

NCT03857321
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
Insulin, Placebo, intranasal nebulizer-like device
Drug · Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions
Placebo, AMG 479, AMG 655
Other · Drug
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 37 more
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
70
States / cities
Little Rock, Arkansas • Concord, California • Encino, California + 60 more
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Insulin Regulation of Lipolysis and Lipolysis Proteins

NCT03866408
Conditions
Obesity
Interventions
Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Obesity, Insulin Resistance
Interventions
MICARDIS® (telmisartan)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Westlake Village, California + 5 more
Conditions
Diabetes Mellitus, Type 2
Interventions
TAK-875, Glimepiride, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more